Literature DB >> 15639632

Total joint replacement of hip or knee as an outcome measure for structure modifying trials in osteoarthritis.

R D Altman1, E Abadie, B Avouac, G Bouvenot, J Branco, O Bruyere, G Calvo, J-P Devogelaer, R L Dreiser, G Herrero-Beaumont, A Kahan, G Kreutz, A Laslop, E M Lemmel, C J Menkes, K Pavelka, L Van De Putte, L Vanhaelst, J-Y Reginster.   

Abstract

OBJECTIVE: The Group for the Respect of Ethics and Excellence in Science (GREES) organized a working group to assess the value of time to joint surgery as a potential therapeutic failure outcome criterion for osteoarthritis (OA) of the hip or knee in the assessment of potential structure modifying agents.
METHODS: PubMed was searched for manuscripts from 1976 to 2004. Relevant studies were discussed at a 1-day meeting.
RESULTS: There are no accepted guidelines for 'time to' and 'indications for' joint replacement surgery. A limited number of trials have examined joint replacement surgery within the study population. Several parameters, particularly joint space narrowing (interbone distance), correlate with surgical intervention. However, at the level of the knee, none of the parameters have positive predictive value for joint replacement surgery better than 30%. In contrast, lack of significant joint space narrowing has a strong negative predictive value for joint replacement surgery (>90%), that remains after controlling for OA pain severity.
CONCLUSION: At this time, GREES cannot recommend time to joint surgery as a primary endpoint of failure for structure modifying trials of hip or knee OA-as the parameter has sensitivity but lacks specificity. In contrast, in existing trials, a lack of progression of joint space narrowing has predictive value of >90% for not having surgery. GREES suggests utilizing joint space narrowing (e.g., >0.3-0.7 mm) combined with a lack of clinically relevant improvement in symptoms (e.g., >/=20-25%) for 'failure' of a secondary outcome in structure modifying trials of the hip and knee.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15639632     DOI: 10.1016/j.joca.2004.10.012

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  22 in total

1.  The role of pain and functional impairment in the decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1909 patients. Report of the OARSI-OMERACT Task Force on total joint replacement.

Authors:  L Gossec; S Paternotte; J F Maillefert; C Combescure; P G Conaghan; A M Davis; K-P Gunther; G Hawker; M Hochberg; J N Katz; M Kloppenburg; K Lim; L S Lohmander; N N Mahomed; L March; K Pavelka; L Punzi; E M Roos; L Sanchez-Riera; J A Singh; M E Suarez-Almazor; M Dougados
Journal:  Osteoarthritis Cartilage       Date:  2010-10-31       Impact factor: 6.576

2.  INTERVENTION AT THE FOOT-SHOE-PEDAL INTERFACE IN COMPETITIVE CYCLISTS.

Authors:  Sinead FitzGibbon; Bill Vicenzino; Sue Ann Sisto
Journal:  Int J Sports Phys Ther       Date:  2016-08

3.  TSG-6 activity as a novel biomarker of progression in knee osteoarthritis.

Authors:  H-G Wisniewski; E Colón; V Liublinska; R J Karia; T V Stabler; M Attur; S B Abramson; P A Band; V B Kraus
Journal:  Osteoarthritis Cartilage       Date:  2013-12-12       Impact factor: 6.576

4.  Effects of medication-treated diabetes on incidence and progression of knee osteoarthritis: a longitudinal analysis of the Osteoarthritis Initiative data.

Authors:  Ivan V Shirinsky; Valery S Shirinsky
Journal:  Rheumatol Int       Date:  2017-02-28       Impact factor: 2.631

5.  Effects of pentosan polysulfate in osteoarthritis of the knee: A randomized, double-blind, placebo-controlled pilot study.

Authors:  Peter Ghosh; Jack Edelman; Lyn March; Margaret Smith
Journal:  Curr Ther Res Clin Exp       Date:  2005-11

6.  Identification of progressors in osteoarthritis by combining biochemical and MRI-based markers.

Authors:  Erik B Dam; Marco Loog; Claus Christiansen; Inger Byrjalsen; Jenny Folkesson; Mads Nielsen; Arish A Qazi; Paola C Pettersen; Patrick Garnero; Morten A Karsdal
Journal:  Arthritis Res Ther       Date:  2009-07-24       Impact factor: 5.156

7.  Glucosamine sulfate--environmental antibacterial activity.

Authors:  Alexander P Rozin
Journal:  Clin Rheumatol       Date:  2009-06-04       Impact factor: 2.980

8.  Hip pain and mobility deficits--hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association.

Authors:  Michael T Cibulka; Douglas M White; Judith Woehrle; Marcie Harris-Hayes; Keelan Enseki; Timothy L Fagerson; James Slover; Joseph J Godges
Journal:  J Orthop Sports Phys Ther       Date:  2009-04       Impact factor: 4.751

9.  Exercise therapy, manual therapy, or both, for osteoarthritis of the hip or knee: a factorial randomised controlled trial protocol.

Authors:  J Haxby Abbott; M Clare Robertson; Joanne E McKenzie; G David Baxter; Jean-Claude Theis; A John Campbell
Journal:  Trials       Date:  2009-02-08       Impact factor: 2.279

Review 10.  Detection of calcium phosphate crystals in the joint fluid of patients with osteoarthritis - analytical approaches and challenges.

Authors:  Alexander Yavorskyy; Aaron Hernandez-Santana; Geraldine McCarthy; Gillian McMahon
Journal:  Analyst       Date:  2008-02-01       Impact factor: 4.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.